“Growing prevalence of cardiovascular diseases, technological advancements using cardio biomarkers combinations and increasing point of care (POC) testing have fueled the growth of the global cardiac biomarkers testing market”
The global cardiac biomarkers testing market size was $76.38 billion in 2018 and is estimated to reach $18.23 billion by 2026, registering a CAGR of 11.4% during 2019 – 2026. The research offers a comprehensive analysis of the major segments including the changing market trends, key winning policies, drivers and opportunities, and competitive scenario.
Download Sample Report https://www.alliedmarketresearch.com/request-sample/5284
The growing prevalence of cardiovascular diseases, technological advancements using cardio biomarkers combinations and increasing point of care (POC) testing have increased the growth of the global cardiac biomarkers testing market. Whereas, the complex process related to the course and several stringent government regulations hamper market growth. However, an increase in the use of personalized medicine and rise in POC testing using cardiac biomarkers are expected to provide lucrative opportunities in the market.
The myocardial infraction segment to lead during 2019-2026
On the basis of application, the myocardial infraction segment accounted for almost two-fifths of the total market share in 2018 and is expected to lead the trail throughout the forecast period. In comparison to all other cardiovascular diseases (CVDs), the high prevalence rate of this segment has driven its growth. On the other hand, the congestive heart failure segment is accounted to register the highest CAGR of 12.3% during 2019-2026.
The troponins segment held the major share during 2019-2026
Based on application, the troponins segment held the major share accounting for nearly two-fifths of the total market share in 2018. The prodigious specificity and the ability to accurately detect the cardiac events of acute coronary syndrome, MI, and other cardiac injuries have augmented the growth of the segment. Whereas, the IMA segment is estimated to register the fastest CAGR of 12.8% during the forecast period.
North America to lead the market share during 2019-2026
On the basis of regions, North America contributed to the highest share accounting for more than one-third of the total market in 2018 and is estimated to dominate throughout the forecast period. Increase in demand for cardiac testing, high CVD prevalence rate, and increase in awareness for cardiac diagnostics solutions have driven the growth. On the other hand, the Asia Pacific region is expected to grow at the fastest CAGR of 12.8% throughout the forecast period.
Leading market players –
Leading market players analyzed in the report include Roche Diagnostics, Abbott Laboratories, Thermo Fisher Scientific, Becton, Tosoh Corporation, BioMerieux, Danaher Corporation, Dickinson and Company, Bio-Rad Laboratories, Siemens Healthcare, and PerkinElmer Inc.
Read More https://www.alliedmarketresearch.com/press-release/cardiac-biomarkers-testing-market.html
Contact Us:-
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
